Another large market patent protected for Klaria’s products
Klaria’s drug delivery technology receives patent in Mexico.
Klaria Pharma Holding AB (Klaria) today announces the addition of Mexico to the countries in which Klaria’s products will enjoy patent protection. With a population of over 125 million people, Mexico represents an important market for Klaria’s products.
The combined population of Mexico, Canada and the US is nearly 500 million people. In all markets, the patent covers the underlying drug delivery technology upon which Klaria’s products are based. Klaria currently owns exclusive, worldwide, fee-free and permanent rights to exploit this technology in the areas of migraine and breakthrough cancer pain.
”The granting of the patent in Mexico completes the patent protection we have been seeking for all of North America. Mexico joins Canada and of course the US in the expanding list of areas in which our products will enjoy patent protection. In fact, the US patent will extend into 2029”, said Dr. Scott Boyer, CEO of Klaria Pharma Holding AB.
Today patent protection is available in Australia, Israel, Japan, Canada, China, Mexico, New Zeeland, Russia, South Africa, South Korea, Sweden and USA.
For more information, visit Klaria Pharma Holdings website klaria.com or contact:
Scott Boyer, CEO, Klaria Pharma Holding AB (publ)
Tel: 08-446 42 99 / 0730-71 64 62
This is Klaria Pharma Holding AB
Klarias business concept is based on developing innovative products with clear competitive advantages in the therapy areas of migraine and breakthrough cancer pain. Klaria’s products are based on a patented drug delivery film which is combined with clinically-tested and established active drugs substances. Klaria is listed on Nasdaq First North under the name KLAR. Remium Nordic AB is the Certified Advisor for Klaria Pharma Holding AB. The complete company description can be downloaded from klaria.com.